Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.30 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.30 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.30 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.30 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.30 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.30 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.30 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700238 | 0.75 | PTGS2 (0.40) | PTGS2MAPTLMNAHPGDMEN1 | |
| SCHEMBL1851644 | 0.75 | KMT2A (0.41) | MAPTHPGDMEN1ALDH1A1KMT2A | |
| SCHEMBL1902680 | 0.70 | KMT2A (0.34) | MAPTHPGDMEN1ALDH1A1GLA | |
| SCHEMBL1900677 | 0.70 | L3MBTL1 (0.36) | CYP19A1MAPTLMNAHPGDALDH1A1 | |
| SCHEMBL16911497 | 0.66 | — | — | |
| SCHEMBL16912032 | 0.66 | — | — | |
| SCHEMBL13322631 | 0.65 | CREBBP (0.48) | MAPTLMNA | |
| SCHEMBL9963176 | 0.64 | CYP19A1 (0.66) | CYP19A1PTGS2LMNAMEN1GAA | |
| SCHEMBL19088674 | 0.64 | PDE1A (0.45) | PTGS2MAPTHPGDMEN1ALDH1A1 | |
| SCHEMBL23399527 | 0.63 | KMT2A (0.43) | PTGS2MAPTLMNAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | CYP19A1 3806/4885PTGS2 4337/4885MAPT 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.